Endo International says ‘good’ cash position expected at end of year

By Devika Patel

Knoxville, Tenn., Sept. 12 – Endo International plc has about $1.1 billion of unrestricted cash on the balance sheet and expects to end the year with a “good” cash position.

“We are exiting the second quarter with about $1.1 billion of unrestricted cash on our balance sheet,” executive vice president and chief financial officer Blaise Coleman said at the Morgan Stanley Global Healthcare Conference in New York on Wednesday.

“When you look at our guidance, we expect to end the year with unrestricted cash that’s somewhere between $690 million to $750 million and that’s a good position for us,” he said.

Endo is a Dublin, Ireland-based specialty pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.